AstraZeneca Investor Day Presentation Deck
Enhertu: a new standard of care
for patients with HER2-positive metastatic breast cancer
20
●
●
Today: 3rd-line+ mBC
Strong launch trajectory:
market leader in every
major country launched¹
>7,000 patients treated to
date
Partnering with healthcare
practitioners with
treatment-specific guidance
1. UK National Health Service - Cancer Drugs Fund, AstraZeneca market studies.
2022: 2nd-line mBC
DESTINY-Breast03:
unprecedented benefit in
2nd line
●
• Consistent efficacy across
all sub-groups
Safety profile and
prolonged PFS benefit
supports extended duration
on therapy
●
Future: earlier settings,
combinations
Efficacy and safety profile
support development in 1st
line and adjuvant settings
Opens opportunity to treat
with curative intent
• An Enhertu option for
every patient with HER2+
cin
breast cancer
ENHERTUView entire presentation